Skip to main content
PepStack
Blutwerte · Marker

Immunglobulin G

Immunoglobulin G · IgG

Immunsystem
Einheit:
g/L
Abbreviation
IgG

IgG quantifies the concentration of immunoglobulin G antibodies in the blood.

Reference Ranges

Reference
716g/L
7
16
LowNormalHigh
Reference
Unit · g/L

Reference ranges may vary slightly based on laboratory standards and methods.

Overview

Übersicht

Immunoglobulin G (IgG) is the most abundant type of antibody found in the circulation, playing a crucial role in the body's immune response by identifying and neutralizing pathogens such as bacteria and viruses. IgG is produced by plasma cells and is involved in the secondary immune response, providing long-term protection. Clinically, IgG levels are significant in diagnosing and monitoring various conditions, including autoimmune disorders, infections, and immunodeficiencies. Elevated IgG levels can indicate chronic infections, autoimmune diseases, or liver disease, while low levels may suggest immunodeficiency or protein-losing conditions. In the context of athletic performance and biohacking, IgG's role in immune function is critical, as maintaining optimal immune health is essential for recovery and performance. IgG glycosylation patterns have been studied in relation to aging, with certain glycan profiles associated with inflammaging, a chronic low-grade inflammation linked to aging. Researchers have found that IgG levels can be influenced by various factors, including infections, autoimmune activity, and genetic predispositions. Testing for IgG does not typically require fasting, but levels can be affected by acute infections or recent vaccinations, which should be considered when interpreting results.

Klinische Bedeutung

Elevated IgG levels may indicate chronic infections, autoimmune diseases, or liver disease. Reduced IgG levels can suggest immunodeficiency, protein-losing conditions, or certain genetic disorders.

Dynamics

Trend Interpretation

Rising Values

Progressively rising IgG levels may suggest worsening of chronic infections or autoimmune activity. Retesting is recommended in 4-6 weeks.

Falling Values

Progressively falling IgG levels could indicate improving infection control or potential immunodeficiency.

Re-test Interval

4-6 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Chronic infections
  • Autoimmune diseases
  • Liver disease
  • Chronic inflammation
  • Multiple myeloma
Cause

Low Levels

  • Immunodeficiency
  • Protein-losing enteropathy
  • Nephrotic syndrome
  • Chronic lymphocytic leukemia
  • Genetic immunoglobulin deficiencies
Protocol

How to Optimize

Lever

Lifestyle

  • Regular exercise
  • Adequate sleep
  • Stress management
Lever

Nutrition

  • Balanced diet rich in vitamins and minerals
  • Probiotic-rich foods
  • Omega-3 fatty acids
Lever

Supplementation

  • Vitamin D
  • Zinc
  • Probiotics

Note:

Consult a healthcare provider before starting any supplementation, especially if underlying conditions are present.

Testing Guidelines

Fasting Not Required
Not Time-Sensitive

Testing Frequency

Annually for individuals with immune-related conditions or as advised by a healthcare provider.

Interfering Factors

  • Recent infections
  • Vaccinations
  • Immunosuppressive therapy

Open Research Questions

Current research suggests that reference ranges for immunoglobulin G (IgG) glycosylation patterns in aging and their implications for inflammation modulation remain understudied. Researchers have not yet established optimal targets for IgG biomarkers in conditions like neuromyelitis optica and autoimmune astrocytopathy. Additionally, clinical questions regarding the long-term efficacy of treatments targeting IgG-related disorders and the role of IgG glycosylation in disease progression remain unanswered.

25 Research Publications

1,059

Total Citations

6

Human/RCT

13.2

Avg. Influence

2025

Latest

Sort
Filter
#01

Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.

Case ReportInfluence48.0
477
Researchers characterized a novel autoimmune central nervous system disorder with glial fibrillary acidic protein (GFAP)-IgG as a biomarker in 102 patients. They found that GFAP-IgG positivity is highly specific for an immunotherapy-responsive autoimmune CNS disorder. The study also noted that the presence of GFAP-IgG in cerebrospinal fluid (CSF) correlates with specific clinical phenotypes.
View on PubMed
#02

Immunoglobulin G glycosylation in aging and diseases.

ReviewInfluence11.0
348
Researchers found that the glycosylation patterns of Immunoglobulin G (IgG) vary significantly with age and disease states, making it a potential biomarker for general health. They noted that changes in IgG glycosylation can influence immune function and may play a role in disease progression, suggesting its analysis could enhance existing disease biomarkers.
View on PubMed
#03

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.

Consensus StatementInfluence4.0
76
Researchers emphasized the importance of cerebrospinal fluid (CSF) analysis for diagnosing multiple sclerosis (MS), focusing on intrathecal immunoglobulin G (IgG) synthesis. They found that κ-free light chains (FLCs) are a promising new biomarker with high diagnostic accuracy, suggesting their inclusion in future MS diagnostic criteria.
View on PubMed
#04

High-throughput analysis of immunoglobulin G glycosylation.

ReviewInfluence2.0
34
Researchers reviewed high-throughput methods for analyzing Immunoglobulin G (IgG) glycosylation, which is important for understanding its functional relevance in health and disease. They emphasized the need for robust and affordable methodologies to facilitate the discovery of glycan biomarkers in clinical settings.
View on PubMed
#05

Immunoglobulin G glycans - Biomarkers and molecular effectors of aging.

Review
32
Researchers reviewed the role of Immunoglobulin G (IgG) glycans in aging, highlighting their potential as biomarkers and molecular effectors. They summarized studies on how IgG glycosylation patterns change with age and discussed the implications of these changes for understanding the aging process and age-related diseases.
View on PubMed
#06

Glycosylation and Aging.

Review
20
Researchers explored the relationship between glycosylation and aging, particularly focusing on immunoglobulin G (IgG) N-glycome changes. They found that agalactosylated IgG glycans may modulate inflammation levels associated with aging, proposing the IgG glycopattern as a potential biomarker for healthy aging.
View on PubMed
#07

Biochemical biomarkers for multiple sclerosis.

Review
18
Researchers reviewed biochemical biomarkers for multiple sclerosis (MS), highlighting the significance of immunoglobulin G oligoclonal bands (OCB) in CSF for diagnosis. They noted that κ-free light chains (FLCs) have shown higher sensitivity and specificity than OCB, suggesting their potential role in MS diagnosis and prognosis.
View on PubMed
#08

Glycosylation of immunoglobin G in tumors: Function, regulation and clinical implications.

Review
14
Researchers summarized the impact of Immunoglobulin G (IgG) glycosylation on tumor immunity and progression. They noted that specific glycosylation modifications correlate with tumor characteristics, suggesting that IgG glycosylation could be a target for improving tumor diagnosis and treatment strategies.
View on PubMed
#09

Laboratory diagnosis of Zika virus.

Review
10
Researchers outlined laboratory diagnosis recommendations for Zika virus infection, emphasizing the detection of ZIKV-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. They found that combining serologic and molecular testing is crucial for accurate diagnosis, especially in pregnant women.
View on PubMed
#10

Neuromyelitis optica.

ReviewInfluence1.0
8
Researchers reviewed advancements in neuromyelitis optica, focusing on the serum antibody biomarker neuromyelitis optica immunoglobulin G (NMO-IgG). They found that NMO-IgG distinguishes neuromyelitis optica from multiple sclerosis and is now part of new diagnostic criteria. The study also identified aquaporin-4 as the molecular target of NMO-IgG, enhancing understanding of the disease.
View on PubMed

Publication Trend

Research publications about Immunglobulin G over time

9total
1
'07
1
'17
1
'19
1
'21
1
'22
1
'23
2
'24
1
'25

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer